Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...

As part of Business Publications Corp.’s Envision Iowa think tank series, we spoke Aug. 22 with three experts who work with ...

American food safety expert, Dr. Darin Detwiler shares his key takeaways from Food Integrity Global 2024, hosted by New Food ...

Warner Bros. TV Group chairman and CEO Channing Dungey will deliver a keynote address at Mipcom in Cannes next month.

ISG and Other Leaders to Discuss AI’s Impact on CX at ISG Digital Business Summit in Frankfurt. Takeaway Points ISG and Other ...

Follow live coverage from the Reform UK conference in Birmingham where party MPs Nigel Farage, Lee Anderson and Richard Tice ...

Tuloso-Midway ISD held its State of the District event Thursday, including remarks from Texas Education Agency head Mike ...

We recently compiled a list of the Jim Cramer’s Top 12 Must-Watch Stocks. In this article, we are going to take a look at ...

The FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy as first-line treatment for adults with malignant pleural mesothelioma.

Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared ...

The first overall survival analysis of the KEYNOTE-522 trial showed positive outcomes with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab monotherapy vs neoadjuvant ...

Peter Schmid, MD, PhD, discusses his key takeaways from the phase 3 KEYNOTE-522 trial and the updated findings presented at ...